Current prospects and challenges of nanomedicine delivery in prostate cancer therapy

Area of Science:

• Oncology
• Nanomedicine
• Drug Delivery

Background:

• Systemic delivery of anticancer drugs for prostate cancer faces challenges including poor drug distribution, reduced bioavailability, and significant side effects.
• Nanomedicine-based drug delivery systems offer a promising solution to overcome these limitations by improving the therapeutic index.
• Targeting prostate tumors via locoregional delivery can enhance efficacy and minimize systemic exposure to therapeutics.

Purpose of the Study:

• To review the current landscape of nanomedicine applications in prostate cancer therapy.
• To comprehensively describe the advantages and limitations of both systemic and locoregional delivery routes for nanomedicines.
• To highlight the potential and challenges associated with nanomedicine-based localized prostate cancer treatment.

Main Methods:

• Literature review of systemic and locoregional nanomedicine delivery strategies for prostate cancer.
• Analysis of the benefits and drawbacks of different nanomedicine delivery approaches.
• Discussion of current prospects and future challenges in the field.

Main Results:

• Nanomedicine improves anticancer drug delivery, leading to higher effective doses and reduced off-target effects.
• Locoregional delivery of nanomedicines demonstrates superior efficacy and reduced systemic toxicity compared to systemic administration.
• Significant advancements in nanomedicine offer enhanced therapeutic options for prostate cancer management.

Conclusions:

• Nanomedicine holds significant potential for improving prostate cancer treatment outcomes.
• Locoregional delivery strategies using nanomedicines are crucial for maximizing therapeutic benefits while minimizing adverse effects.
• Further development of localized nanomedicine-based therapies is essential for advancing prostate cancer care.